ClinicalTrials.gg
Sign In
RecruitingNCT07784842Updated Aug 25, 2026

True Muscle Transplantation Surgery Versus Augmented Semi Hang Back Recession in Large Angle Exotropia: Evaluation of Efficacy and Lateral Gaze Incomitance

An interventional study of True Muscle Transplantation Surgery and Augmented Semi hang back Recession in Large Angle Exotropia, sponsored by Hassnaa Mohamed Abdelhameed Ahmed. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Hassnaa Mohamed Abdelhameed Ahmed · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2026, registered Aug 2026).
  • Started Mar 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Sex
All
01

Study summary

This a randomized clinical trial comparing True muscle transplantation surgery versus Augmented Semi hang back recession for treatment of large angle exotropia

Read the detailed description

large angle exotropia is a challenging to treat surgically .40 patients will be randomized into 2 groups and followed for 6 months to assess alignment and success rate

02

Conditions studied

  • Large Angle Exotropia

Browse trials for

Keywords

  • exotropia,strabismus,muscle transplantation,augmented recession
03

In context

Exotropia

58 studies on the registry are indexed under Exotropia; 13 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 49 interventional studies indexed under Exotropia.

Browse Exotropia studies →

Lead sponsor

This is the only study on the registry with Hassnaa Mohamed Abdelhameed Ahmed as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with large angle exotropia more than 50 prism diopters.
  2. No previous squint surgery.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe ocular surface diseases as ocular cicatricial pemphigoid and severe dry eye.
  2. Severe systemic illness that prevents general anesthesia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    True Muscle Transplantation Surgery

    Patients in this group will undergo True Muscle Transplantation Surgery For treatment of large angle exotropia

    Procedure: True Muscle Transplantation Surgery

  • Experimental
    Augmented Semi hang back Recession

    Patients in this group will undergo Augmented Semi hang back Recession for treatment of large angle exotropia

    Procedure: Augmented Semi hang back Recession

Interventions

  • ProcedureTrue Muscle Transplantation Surgery

    true Muscle Transplantation surgery for treatment of large angle Exotropia

  • ProcedureAugmented Semi hang back Recession

    Augmented Semi hang back Recession for treatment of large angle Exotropia

06

What researchers measure

Primary outcomes

  1. Surgical success rate at 6 months

    Proportion of patients with ocular alignment within 10 prism diopters of orthotropia measured by prism and alternate cover test

    Time frame: 6 months post-surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2026, 7 months after the start.

Of 29 interventional studies with no phase under Exotropia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 25, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Jan 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07784842
Lead sponsor
Hassnaa Mohamed Abdelhameed Ahmed
Responsible party
Hassnaa Mohamed Abdelhameed Ahmed (Assistant Lecturer of Ophthalmology, Minia University, Minia University) — Sponsor-investigator
First posted
Aug 25, 2026
Start date
Mar 1, 2026
Primary completion
Oct 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Hassnaa Mohamed Abdelhameed, Assistant lecturer
Contact
hasnaa.abdelhamid@mu.edu.eg
+201158861290

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Exotropia →

Start the discussion